Northern Trust Corp Sells 25,992 Shares of Athersys, Inc. (NASDAQ:ATHX)

Northern Trust Corp decreased its position in Athersys, Inc. (NASDAQ:ATHX) by 1.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,009,459 shares of the biopharmaceutical company’s stock after selling 25,992 shares during the period. Northern Trust Corp owned 1.02% of Athersys worth $3,516,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ATHX. Teacher Retirement System of Texas raised its position in Athersys by 60.0% during the 4th quarter. Teacher Retirement System of Texas now owns 17,237 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 6,463 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Athersys in the third quarter valued at about $33,000. Aurum Wealth Management Group LLC bought a new stake in shares of Athersys in the fourth quarter valued at about $38,000. Squarepoint Ops LLC purchased a new stake in Athersys in the third quarter worth about $46,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in Athersys during the 3rd quarter worth about $65,000. 27.87% of the stock is currently owned by institutional investors.

ATHX opened at $1.69 on Thursday. The firm has a market capitalization of $362.69 million, a PE ratio of -4.55 and a beta of -1.54. The business’s 50-day moving average is $1.88 and its two-hundred day moving average is $1.94. Athersys, Inc. has a 1 year low of $1.53 and a 1 year high of $3.39.

Athersys (NASDAQ:ATHX) last released its quarterly earnings results on Wednesday, March 24th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). As a group, research analysts predict that Athersys, Inc. will post -0.43 earnings per share for the current fiscal year.

Separately, Zacks Investment Research raised shares of Athersys from a “sell” rating to a “hold” rating in a research report on Tuesday, March 30th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Athersys has an average rating of “Buy” and a consensus target price of $9.00.

In other Athersys news, CEO William Lehmann, Jr. sold 25,000 shares of Athersys stock in a transaction on Thursday, March 18th. The shares were sold at an average price of $1.91, for a total value of $47,750.00. Following the transaction, the chief executive officer now directly owns 443,836 shares of the company’s stock, valued at $847,726.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 40,000 shares of company stock valued at $77,300. 12.60% of the stock is owned by insiders.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Featured Story: Learning About the VIX – Volatility Index

Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.